Boston-based biotech Ratio Therapeutics has doubled its funding at a stroke with a $20 million Series A that will be used to usher its targeted radiotherapies into clinica
Aktis Oncology has gone back for another bite of the cherry in its Series A round, adding another $84 million to the $72 million raised last year to help bring its radiopharmaceuticals to m
The inaugural Targeted Radiopharmaceuticals Summit US will bring together a worldwide community of specialists to address long-standing challenges in radiopharmac
The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy developed by Novartis' Advanced Accelerator Applications (AAA) subsidiary wh
